【SR-7　評価シート　エビデンス総体】

診療ガイドライン	乳癌診療ガイドライン　薬物療法　2022年版
対象	HER2陰性転移・再発乳癌（女性）
介入	ベバシズマブ+化学療法
対照	化学療法

＊バイアスリスク，非直接性
各ドメインの評価は「高（−2）」，「中／疑い（−1）」，「低（0）」の3 段階。
まとめは「高（−2）」，「中（−1）」，「低（0）」の3 段階でエビデンス総体に反映させる。
＊＊上昇要因
各項目の評価は「高（+2）」，「中（+1）」，「低（0）」の3 段階。
まとめは「高（+2）」，「中（+1）」，「低（0）の3 段階でエビデンス総体に反映させる。

エビデンス総体

アウトカム	研究デザイン／研究数	＊バイアスリスク	＊非一貫性	＊不精確性	＊非直接性	＊その他（出版バイアスなど）	＊上昇要因（観察研究）	リスク人数（アウトカム率）対照群分母	対照群分子	（%）	介入群分母	介入群分子	（%）	効果指標（種類）	効果指標統合値	95%信頼区間	＊＊エビデンスの強さ	＊＊＊重要性	コメント
OS	RCT/8	−1	0	0	0	0		1952	-	-	2864	-	-	HR	0.94	0.86-1.01	A	9	有意水準に達しない
PFS	RCT/9	−1	−1	0	0	0		2046	-	-	2961	-	-	HR	0.73	0.65-0.81	A	8	Beva群で有意にPFS良好。異質性ありの判定であるが、全体の傾向は同じでありこのSRをそのまま採用。
ORR	RCT/9	−1	−1	0	0	−1		1718	479	28	2418	1053	44	RR	1.49	1.30-1.70	A	6	Beva群で有意にORR良好。異質性ありの判定であるが、全体の傾向は同じでありこのSRをそのまま採用。
QOL	RCT/2																B	7	2試験のQOL評価の指標が異なるのでMA, 定量的SRは困難。
Toxicity(therapy discontinuation)	RCT/9	−1	−1	−1	0	−1		1985	263	13	2948	499	17	RR	1.42	1.10-1.82	A	7	Beva群で有意にToxicity(therapy discontinuation)が高い。
Toxicity(G3以上)	RCT/6	−1	0	0	0	−1		1326	425	32	2257	1003	44	RR	1.51	1.30-1.75	A	7	Beva群で有意にToxicity(グレード3以上)が高い。

コメント（該当するセルに記入）

Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Random, 95% CI
Brufsky 2011 (RIBBON-2)	-0.1054	0.121	11.7%	0.90 [0.71, 1.14]
Miles 2010 (AVADO)	0.0392	0.1029	16.2%	1.04 [0.85, 1.27]
Miles D 2017 (MERiDiAN)	-0.2107	0.1447	8.2%	0.81 [0.61, 1.08]
Miller 2005 (AVF2119g)	0.0677	0.1174	12.4%	1.07 [0.85, 1.35]
Miller 2007 (E2100)	-0.1508	0.0836	24.5%	0.86 [0.73, 1.01]
Minckwitz 2014 (TANIA)	-0.0408	0.1192	12.0%	0.96 [0.76, 1.21]
Robert 2011 (RIBBON-1 Cape cohort)	-0.1625	0.1528	7.3%	0.85 [0.63, 1.15]
Robert 2011 (RIBBON-1 T+Anthra cohort)	0.0296	0.1484	7.8%	1.03 [0.77, 1.38]
Total (95% CI)			**100.0%**	**0.94 [0.86, 1.01]**

Heterogeneity: Tau² = 0.00; Chi² = 5.34, df = 7 (P = 0.62); I² = 0%
Test for overall effect: Z = 1.60 (P = 0.11)



Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Random, 95% CI
Brufsky 2011 (RIBBON-2)	-0.2485	0.1009	12.5%	0.78 [0.64, 0.95]
Martin 2011	-0.2357	0.2037	5.5%	0.79 [0.53, 1.18]
Miles 2010 (AVADO)	-0.3147	0.0752	15.2%	0.73 [0.63, 0.85]
Miles D 2017 (MERiDiAN)	-0.3857	0.1468	8.6%	0.68 [0.51, 0.91]
Miller 2005 (AVF2119g)	-0.0202	0.123	10.4%	0.98 [0.77, 1.25]
Miller 2007 (E2100)	-0.5798	0.0786	14.8%	0.56 [0.48, 0.65]
Minckwitz 2014 (TANIA)	-0.2877	0.1054	12.0%	0.75 [0.61, 0.92]
Robert 2011 (RIBBON-1 Cape cohort)	-0.3857	0.1176	10.9%	0.68 [0.54, 0.86]
Robert 2011 (RIBBON-1 T+Anthra cohort)	-0.2614	0.1273	10.0%	0.77 [0.60, 0.99]
Total (95% CI)			**100.0%**	**0.73 [0.65, 0.81]**

Heterogeneity: Tau² = 0.01; Chi² = 18.13, df = 8 (P = 0.02); I² = 56%
Test for overall effect: Z = 5.66 (P < 0.00001)



Study or Subgroup	Beva+CTx Events	Beva+CTx Total	CTx Events	CTx Total	Weight	Risk Ratio M-H, Random, 95% CI
Brufsky 2011 (RIBBON-2)	143	362	53	179	12.0%	1.33 [1.03, 1.73]
Martin 2011	50	97	39	94	10.1%	1.24 [0.91, 1.69]
Miles 2010 (AVADO)	243	407	96	207	16.3%	1.29 [1.09, 1.52]
Miles D 2017 (MERiDiAN)	129	239	80	242	14.0%	1.63 [1.32, 2.02]
Miller 2005 (AVF2119g)	46	232	21	230	5.6%	2.17 [1.34, 3.52]
Miller 2007 (E2100)	112	229	54	243	11.5%	2.20 [1.68, 2.88]
Minckwitz 2014 (TANIA)	38	182	31	185	6.7%	1.25 [0.81, 1.91]
Robert 2011 (RIBBON-1 Cape cohort)	115	325	38	161	9.9%	1.50 [1.09, 2.05]
Robert 2011 (RIBBON-1 T+Anthra cohort)	177	345	67	177	14.0%	1.36 [1.09, 1.68]
Total (95% CI)		**2418**		**1718**	**100.0%**	**1.49 [1.30, 1.70]**
Total events	1053		479			

Heterogeneity: Tau² = 0.02; Chi² = 17.40, df = 8 (P = 0.03); I² = 54%
Test for overall effect: Z = 5.87 (P < 0.00001)



Study or Subgroup	Beva+CTx Events	Beva+CTx Total	CTx Events	CTx Total	Weight	Risk Ratio M-H, Random, 95% CI
Brufsky 2011 (RIBBON-2)	61	458	16	221	10.0%	1.84 [1.09, 3.11]
Martin 2011	22	96	12	89	8.2%	1.70 [0.89, 3.23]
Miles 2010 (AVADO)	58	499	28	231	11.8%	0.96 [0.63, 1.46]
Miles D 2017 (MERiDiAN)	76	239	55	242	14.3%	1.40 [1.04, 1.88]
Miller 2005 (AVF2119g)	28	229	29	215	10.7%	0.91 [0.56, 1.47]
Miller 2007 (E2100)	82	365	68	346	14.5%	1.14 [0.86, 1.52]
Minckwitz 2014 (TANIA)	45	245	19	238	10.3%	2.30 [1.39, 3.81]
Robert 2011 (RIBBON-1 Cape cohort)	48	404	24	201	11.1%	1.00 [0.63, 1.58]
Robert 2011 (RIBBON-1 T+Anthra cohort)	79	413	12	202	9.1%	3.22 [1.80, 5.77]
Total (95% CI)		**2948**		**1985**	**100.0%**	**1.42 [1.10, 1.82]**
Total events	499		263			

Heterogeneity: Tau² = 0.09; Chi² = 23.02, df = 8 (P = 0.003); I² = 65%
Test for overall effect: Z = 2.73 (P = 0.006)



Study or Subgroup	Beva+CTx Events	Beva+CTx Total	CTx Events	CTx Total	Weight	Risk Ratio M-H, Random, 95% CI
Brufsky 2011 (RIBBON-2)	161	458	50	221	14.2%	1.55 [1.18, 2.04]
Miles 2010 (AVADO)	187	499	72	231	17.0%	1.20 [0.96, 1.50]
Miles D 2017 (MERiDiAN)	179	238	96	233	20.3%	1.83 [1.54, 2.16]
Minckwitz 2014 (TANIA)	145	245	109	238	20.1%	1.29 [1.09, 1.54]
Robert 2011 (RIBBON-1 Cape cohort)	143	404	44	201	13.2%	1.62 [1.21, 2.17]
Robert 2011 (RIBBON-1 T+Anthra cohort)	188	413	54	202	15.3%	1.70 [1.32, 2.19]
Total (95% CI)		**2257**		**1326**	**100.0%**	**1.51 [1.30, 1.75]**
Total events	1003		425			

Heterogeneity: Tau² = 0.02; Chi² = 13.06, df = 5 (P = 0.02); I² = 62%
Test for overall effect: Z = 5.50 (P < 0.00001)